https://www.selleckchem.com/pr....oducts/mg-101-alln.h
A previous Phase I/II study demonstrated that TAS-102 (trifluridine/tipiracil [FTD/TPI]) plus bevacizumab (Bev) has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing the efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer. This is a multicenter, single-arm Phase II study included patients ≥70years old with previously untreated, unresectable metastatic colorectal cancer. Tre
Like
Comment
Share
